- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...
Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/alpha-announces-financial-results-for-fourth-quarter-and-full-year-2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results